Results 221 to 230 of about 16,927,067 (395)

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

The utilisation and cost of social care after hip fracture: a prospective observational cohort study. [PDF]

open access: yesAge Ageing
Goh EL   +8 more
europepmc   +1 more source

MOESM1 of Social media to supplement point-of-care ultrasound courses: the â sandwich e-learningâ approach. A randomized trial

open access: gold, 2016
Dorothea Hempel   +7 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

Health and social care professionals' expectations for e-leadership in the digital transformation: a qualitative study. [PDF]

open access: yesBMC Health Serv Res
Kaihlanen AM   +5 more
europepmc   +1 more source

Transition from children’s to adults’ services for young people using health or social care services (NICE Guideline NG43)

open access: yesArchives of Disease in Childhood: Education & Practice Edition, 2017
Emily R Willis, J. E. McDonagh
semanticscholar   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy